Today's Edition


 • Greenbrier, Monroe County Road Projects Announced Following Special Legislative Session

 • Paul lasts the distance against Mayweather in exhibition

 • Greenbrier Valley Aquatic Center Seeks New Team Leader

 • Elder abuse prevention, courthouse upgrades, Arts and Recs considered by Greenbrier County Commission

 • DEA: Companies had 'systematic failure' in monitoring pills

 • RSVP for Active SWV's 1st Annual WV Workplace Wellness Conference

 • FBI subpoenas info on readers of news story on slain agents

 • Another jump in prices tightens the squeeze on US consumers

 • Federal probe: Protest not broken up due to Trump photo op

 • Medicare copays for new Alzheimer's drug could reach $11,500

 • Neighbor Dispute Leads To Battle Using Weed-Eater, Homemade Spear

 • Dear Abby: Friday, June 11

 • Let Me Do You A Flavor: Pulled Pork

 • Spartans Shocked By Oak Hill In Section Finals

 • UPDATED: Ronceverte Commission Meeting Agenda

In The News:

DEA: Companies had 'systematic failure' in monitoring pills

CHARLESTON, W.Va. (AP) — A retired high-ranking official with the Drug Enforcement Administration has testified that three large opioid distributors had a “systematic failure” in monitoring suspicious pill orders.
Joe Rannazzisi, former head of the Office of Diversion Control for the DEA from 2006 to 2015, testified Tuesday in Charleston in a landmark civil case brought by Cabell County and the city of Huntington that accuses AmerisourceBergen, Cardinal Health Inc. and McKesson Corp. of fueling the U.S. opioid epidemic.
The companies say poor communication and pill quotas set by federal agents are to blame, along with a rise in prescriptions written by doctors.
Rannazzisi testified that the defendants didn’t report suspicious orders to the DEA due to a failure with their monitoring systems, The Herald-Dispatch reported. He said the DEA asked the companies in 2005 to rein in their distribution practices. A follow-up review of pill shipping data found the flow of pills was not reduced.
He testified that McKesson later told the DEA that its suspicious-pill monitoring system was not picking up generic drugs in the hydrocodone class.
The failures led to suspension orders being issued against McKesson in 2006, AmerisourceBergen in 2007 and Cardinal Health in 2007 and 2012, Rannazzisi testified.
Rannazzisi did not personally review distributors’ monitoring systems, participate in on-site visits or speak to any distributors but McKesson in 2005, McKesson attorney Paul Schmidt said.
Rannazzisi also testified that he did not know of any investigations showing the defendants had shipped orders they believed were suspicious.


Next Post

Welcome Back!

Login to your account below

Create New Account!

Fill the forms bellow to register

Retrieve your password

Please enter your username or email address to reset your password.

west virginia daily newstaxi how muchupdown